Sugi Predict

Sugi Predict / Compounds / SCHEMBL530947

SCHEMBL530947

SCHEMBL530947

C=CC(OC)c1nccs1

nearest known ligand 0.34

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ NOS1 P29475 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ CTSA P10619 3/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ SMPD3 Q9NY59 1/20 0.30
▸ MAPKAPK2 P49137 1/20 0.30
▸ CNR1 P21554 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3311139 0.72 — —
SCHEMBL4237979 0.71 — —
SCHEMBL9370321 0.71 — —
SCHEMBL22013650 0.71 — —
SCHEMBL324805 0.71 — —
SCHEMBL11578181 0.69 KDM4E (0.35) ALOX5ALDH1A1TSHRNOS1HSD17B10
SCHEMBL7176278 0.68 — —
SCHEMBL1987440 0.67 — —
SCHEMBL12199759 0.67 MEN1 (0.35) ALOX5ALDH1A1TSHRNOS1HSD17B10
SCHEMBL557653 0.66 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030064929-A1 Modulating body/cranial hair growth DURANTON ALBERT (FR) 2003-04-03 — — US claimed
EP-0648488-B1 Method to alter hairgrowth and compositions therefor OREAL (FR) 2000-11-29 — — EP claimed
US-5928654-A Modulating body/cranial hair growth with lipoxygenase/cyclooxygenase inhibitors SOCIETE L'OREAL S.A. (FR) 1999-07-27 — — US claimed
EP-0800815-A2 Use of at least one lypoxygenase inhibitor and at least one cyclo-oxygenase inhibitor to alter hair growth L'OREAL (FR) 1997-10-15 — — EP claimed
EP-0648488-A1 Method to alter hairgrowth and compositions therefor L'OREAL (FR) 1995-04-19 — — EP claimed
US-12037405-B2 Anti-CD70 antibody drug conjugates AMBRX, INC. 2024-07-16 — — US disclosed
US-20240190981-A1 Humanized Anti-CD70 Binding Agents and Uses Thereof SEAGEN INC (US) 2024-06-13 — — US disclosed
US-20240182580-A1 ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES SUTRO BIOPHARMA INC (US) 2024-06-06 — — US disclosed
WO-2024091979-A1 CD276 (B7-H3) ANTIBODY-DRUG CONJUGATES BRICKBIO, INC. (US) 2024-05-02 — — WO disclosed
US-11958909-B2 Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use SUTRO BIOPHARMA, INC. (US) 2024-04-16 — — US disclosed
EP-3488870-B1 ANTI-CD70 ANTIBODY DRUG CONJUGATES AMBRX INC (US) 2024-03-20 — — EP disclosed
US-20240084031-A1 VARIANT TARGET BINDING AGENTS AND USES THEREOF SEAGEN INC. (US) 2024-03-14 — — US disclosed
EP-1229034-A1 Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes Pfizer Products Inc. (US) 2002-08-07 — — EP disclosed
WO-2002051814-A1 BENZOYLPYRIDAZINES MERCK PATENT GMBH (DE) 2002-07-04 — — WO disclosed
WO-2001057036-A1 NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES PFIZER PRODUCTS INC. (US) 2001-08-09 — — WO disclosed
WO-2001057025-A1 PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER PRODUCTS INC. (US) 2001-08-09 — — WO disclosed
EP-0648488-B1 Method to alter hairgrowth and compositions therefor OREAL (FR) 2000-11-29 — — EP disclosed
US-5928654-A Modulating body/cranial hair growth with lipoxygenase/cyclooxygenase inhibitors SOCIETE L'OREAL S.A. (FR) 1999-07-27 — — US disclosed
EP-0800815-A2 Use of at least one lypoxygenase inhibitor and at least one cyclo-oxygenase inhibitor to alter hair growth L'OREAL (FR) 1997-10-15 — — EP disclosed
EP-0648488-A1 Method to alter hairgrowth and compositions therefor L'OREAL (FR) 1995-04-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037405-B2 Anti-CD70 antibody drug conjugates CD74, CD63, CD47 ALOX5 4498/4885ALDH1A1 868/4885TSHR 3236/4885
US-20240084031-A1 VARIANT TARGET BINDING AGENTS AND USES THEREOF CD74, CD2BP2, TSG101 ALOX5 2797/4885ALDH1A1 3624/4885TSHR 2887/4885
US-20240182580-A1 ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES CD74, CD63, CD99 ALOX5 4346/4885ALDH1A1 1241/4885TSHR 1816/4885
US-11958909-B2 Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use DNPEP, LNPEP, ANPEP ALOX5 4691/4885ALDH1A1 4661/4885TSHR 1552/4885
US-20030064929-A1 Modulating body/cranial hair growth ALOX15B, ALOX12, ALOX5 ALOX5 3/4885ALDH1A1 422/4885TSHR 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.